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Results: Out of 108 patients treated with radio (chemo) 
therapy, 76 patients had HPV 16 positivity, 24 HPV 16 & 18, 1 
patient HPV 18 while 6 patients were HPV 16 & 18 negative. 
The mean HPV 16 and HPV 18 viral load was 9.3x106 
copies/10ng DNA and 1.3x106 copies/10 ng DNA respectively. 
At 5 months post treatment, 96 patients had complete 
response, 9 had residual/ recurrent local disease and 3 had 
distant relapse. There was significant reduction in HPV viral 
load at treatment completion, 2 and 5 months post 
treatment in complete responders (p 
Conclusions: A significant reduction in HPV 16 and 18 viral 
load occurs in complete responders after completion of 
radical radio (chemo) therapy. However, further correlation 
between persistence or re-infection of HPV and local 
recurrence is ongoing in this prospective study.  
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Purpose/Objective: Head and neck squamous cell carcinoma 
(HNSCC) associated with HPV has improved response to 
radiation therapy compared to HPV non-associated SCC. 
However, despite this, examples of local failures within 
HNSCC are beginning to emerge. This work aims to 
understand and describe risk factors to radiation resistance 
and increased virulence. HPV-16 non-European (NE) variants 
have been shown to have an 11-fold increased association 
with cervical cancer diagnosis than the European (E) variants. 
Materials and Methods: Our initial analysis of 43 HPV-16 
positive human tumors with PCR that E variants were more 
likely associated with higher stage and lymph node positive 
disease. E2 sequencing was completed for a subset of HPV 16 
variants and analized. The presence of intact E2 DNA has 
shown improved local control and a trend for improved 
disease free survival, for head and neck cancer and cervical 
cancer respectively. To test this, we evaluated five head and 
neck SCC cell lines for presence of intact E2 DNA and mRNA 
using E2 PCR primers. Clonogenic survival assays were 
completed and colony formation was determined. 
Results: E variants were detected more often in higher stage 
HNSCC (79% stage IV v 57% stage I-III, p=0.160) and were also 
more prevalent in node positive disease (82% v 53%, p=0.074). 
Additional tumor HPV 16 variant sequencing needs to be 
completed to more statistical power to detect differences in 
virulence and presentation of malignancy. The subset of 
cancer tissue variant E2 sequencing revealed variation within 
areas know to bind p53 and may affect apoptosis. H&N 
cancer cell line E2 DNA and mRNA expression was confirmed 
and results reveal that E2 disrupted or absent cell lines were 
significantly more radioresistant than their counterparts.  
Conclusions: Preliminary evidence suggests that HPV 16 
variants may be a important factor in evaluation and risk 
stratification. In addition, E2 may serve as a useful tool to 
determine which patients harbor tumors that are 
radioresistant in HPV-positive HNSCC and has implications for 
tumor specific cancer treatments.  
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It is a general belief that patients with oliometastases 
benefit from local ablation of the metastases. Large 
retrospective cohort studies have shown favorable survival 
outcome after surgical resection and radiofrequency 
ablation. Stereotactic body radiation therapy (SBRT) is 
increasingly used for this purpose. Unfortunately, the 
evidence for the use of SBRT of metastases is limited to 
relatively small retrospective studies often with patients with 
various histological types. Colorectal carcinoma (CRC) 
metastasis are often treated with surgery and RFA and it is 
one of the indication where we have the best published 
experience with SBRT.  
A large cohort of CRC patients with metastases primarily in 
the lungs and liver treated with SBRT was published recently 
(1). This study demonstrated promising survival rates of 77, 
33 and 15% at 1, 3 and 5 years after SBRT in a cohort of 
patients who had already received other treatments for 
metastatic disease. Multivariate analysis revealed that WHO 
performance status (0-1) solitary metastasis and small size of 
metastasis (≤ 30 mm) were significantly related to favorable 
survival. The survival of metastatic CRC did not significantly 
differ from the survival of non-CRC metastases patients 
treated with SBRT and the analysis did not identify any tumor 
type with a more favorable outcome when metastases were 
treated with SBRT. 
In general, the approach to metastatic CRC has become more 
aggressive. A number of specialties offer therapies for 
patients with liver oligo-metastases and a multidisciplinary 
team approach in the management of these patients is highly 
important. SBRT may be utilized for a group of patients who 
cannot be treated with surgery. 
 There is sufficient data demonstration that SBRT can be used 
in therapy of CRC metastases, but there is a great need for 
randomized clinical trials to prove the efficacy of SBRT in 
treatment of oligo-metastases and for trials to explore the 
need for systemic therapy along with SBRT. 
Reference:  
1. Mette Marie Fode, Morten Høyer: Survival and 
prognostic factors in 321 patients treated with 
stereotactic body radiotherapy for oligo-
metastases, Radiother Oncol In press 2015  
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As a common deposit for tumor cells, the liver is second only 
to the lymph nodes as a site of metastatic disease. The liver 
is also the most common site of metastatic disease in cancers 
of the large intestine because it is the first major organ 
reached by venous blood draining from the intestinal tract.  
Unfortunately, by the time some patients present with liver 
metastases there is usually evidence of the extensive 
systemic spread of the disease, and patients can no longer be 
considered as candidates for surgery or other local ablative 
treatments. However, there is a subset of patients with a few 
metastases (oligometastases) in which the role of a radical 
local treatment such as stereotactic body radiation therapy 
(SBRT) could change disease progression (1).   
Most patients with liver metastases have a well-preserved 
liver function with absence of underlying diseases. Prediction 
of hepatic toxicity after SBRT in these patients have been 
primarily based on the assumption of a parallel architecture 
where subvolumes of the organ function relatively 
independently and a fraction of the organ can be damaged 
without clinical effect. A complication is only observed if 
more than a critical volume is damaged (2). A critical volume 
of 700 ml of healthy liver (liver-GTV) receiving a total dose of 
less than 15Gy in 3 fractions has been broadly adopted to 
avoid hepatic toxicity (3). 
An accurate correlation between imaging and pathology is 
essential for target definition in SBRT. A good agreement 
between macroscopic pathology and MR imaging has been 
found for a group of colorectal liver metastases, suggesting 
that MR can be used for accurate tumor delineation (4). Pilot 
studies have reported positive integration of 4D PET-CT in 
the target delineation of liver metastases. 
The liver moves with respiration, and can change position 
depending of filling in adjacent anatomical structures. 
Assessment of motion of tumor or tumor surrogates (fiducial 
markers) is mandatory for liver SBRT (5). Management of 
breathing motion during planning and/or treatment 
(abdominal compression, active breathing control, gating, 
tumor tracking) and image guided techniques for daily 
repositioning are required to increase treatment accuracy, 
and make possible to deliver very high doses to the tumor 
while protecting the surrounding organs at risk. 
High local control rates after SBRT for liver metastases have 
been reported in several phase I-II and retrospective trials 
showing a local control between 80% and 100% at 2 years (6-
8).  
The American Association for Physics in Medicine has 
organized an SBRT working group (WGSBRT) to assess tumor 
control probability (TCP) and normal tissue control 
probability (NTCP) values for SBRT applied to different 
organs. In the case of liver metastases, the working liver TCP 
group investigated if outcomes were affected by the dose 
regimen. Local control outcomes were significantly better at 
3 years for BED >100Gy10. 
Toxicity reported after SBRT for liver metastases is in general 
limited. Quality of life has been assessed after liver SBRT 
showing no significant change between baseline and 1, 3, and 
6 months after treatment (9). 
Conclusion: High precision SBRT is an effective technique for 
treatment of liver oligometastases. Using the right dose, 
excellent local control rates can be achieved with limited 
toxicity and without impairment of quality of life.  
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The treatment strategies for many metastatic cancers are 
undergoing a dramatic paradigm shift.  Systemic therapies 
are increasingly tailored to unique characteristics of 
individual tumors.  Routine testing for genetic mutations and 
rearrangements are identifying patients who can benefit from 
“targeted” therapies.  Histology driven chemotherapy is 
commonly being used.  The advent of highly active immune 
modulating therapies have altered treatment strategies for 
many diseases that once had few good systemic options.   
Simultaneously, there is a growing belief that the number 
and location of metastases should also be considered in 
addition to molecular, histology, or immune related factors.  
Patients with metastases limited in number and destination 
organ, oligometastases, are often considered for surgery 
and/or radiation due to reports of long disease free intervals 
following treatment of all known metastases.  Across many 
diseases, it is common to see 20-25% of patients treated for 
limited metastatic disease alive and disease free years later. 
Systemic therapies are often reserved for patients with more 
widespread or “polymetastases”. 
Breast cancer patients often present with limited 
metastases.  Approximately 50% of patients treated on 
clinical trials had 2-4 sites of disease at enrollment.  
Additionally, breast cancer patients with limited metastases 
have improved survival compared to those with more 
extensive metastases.  Following treatment of all known 
metastases median survivals are numerically higher than 
historic populations.  Therefore, NRG BR002 is randomizing 
patients with 1-2 breast cancer metastases to ablative 
therapy (surgery or radiation) plus standard of care therapy 
vs standard of care therapy alone.   
Oligometastases are also common in NSCLC.  A prospective 
phase II study demonstrated long term survivors in patients 
treated with radiotherapy or surgery for oligometaststic 
disease.  Multiple randomized studies have been attempted 
in this population to test consolidation with radiation 
following systemic therapy as well as radiation integrated 
into a systemic therapy treatment platform, however both 
have failed to accrue.  An increasingly useful strategy in 
